Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label basket extension study of D-1553 in KRAS G12C-mutated advanced solid tumors
jRCT2031230636Completed
- Sponsor
- InventisBio
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Open-label, single-arm trial of garsorasib in Nonhematologic neoplasms, sponsored by InventisBio. Primary endpoint: Serious adverse events. Started Mar 2024; status: completed.
02
Drugs
garsorasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230636.